Numerate is the first computational drug design company to take a big-data, big compute approach to the way medicines are designed. The pharma industry has historically been very open to innovation -- the way we discover the biology of cancer today is vastly different than 20 years ago. However, very little has been invested in the past 10 years on the process of taking noisy, biased, complex biological data and translating it to the way we drive our chemistry. Numerate`s technology is the first to be able to process this data and effectively move the design-test cycle to the computer. INstead of many iterations in the lab, we search through billions of possible chemicals on the cloud and only select a handful for synthesis and testing. Our business is to partner around the technology with Pharma and biotech companies, and to be rewarded when our compounds are successful through a mix of cash, milestone and royalty-based payments.